Abstract
AbstractIntraductal oncocytic papillary neoplasm (IOPN) of the pancreas is a distinct entity from intraductal papillary mucinous neoplasms (IPMNs) and is considered one of the precursor lesions of pancreatic cancer. Through immunohistochemistry (IHC) and an artificial intelligence (AI)-based approach, this study aims at characterizing its immune microenvironment. Whole-slide IHC was performed on a cohort of 15 IOPNs, 2 of which harboring an associated adenocarcinoma. The following markers were tested: CD3, CD4, CD8, CD20, CD68, CD163, PD-1, PD-L1, MLH1, PMS2, MSH2, and MSH6. The main findings can be summarized as follows: (i) CD8+ T lymphocytes were the predominant immune cells (p < 0.01); (ii) the vast majority of macrophages were concurrently CD68+ and CD163+; (iii) all tumors showed an activated PD-1/PD-L1 axis, but none had mismatch repair deficiency; (iv) AI-based analysis revealed the presence of 2 distinct regions in each case, namely, Re1, localized at the center of the tumor, and Re2, located at tumor periphery; (v) the infiltrating component of the 2 invasive IOPNs showed a smaller extent of Re1 and a reduced rate of CD4+ cells, as well as a larger extent of Re2 and increased rate of CD8+ cells. IOPNs are lesions enriched in immune cells, with a predominance of CD8+ T lymphocytes and class 2 macrophages. Differently from IPMN-oncogenesis, the progression towards invasive carcinoma is accompanied by an increased rate of CD8+ lymphocytes. This finding may suggest the presence of an active self-immune surveillance in invasive IOPNs, potentially explaining, at least in part, the excellent survival rate of IOPN patients.
Funder
Associazione Italiana per la Ricerca sul Cancro
Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
Fondazione Italiana per la ricerca sulle Malattie del Pancreas
Ministero della Salute
Università degli Studi di Verona
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine
Reference37 articles.
1. Adsay NV, Adair CF, Heffess CS, Klimstra DS (1996) Intraductal oncocytic papillary neoplasms of the pancreas. Am J Surg Pathol 20:980–994. https://doi.org/10.1097/00000478-199608000-00007
2. Basturk O, Esposito I, Fukushima N, Furukawa T, Hong SM, Klöppel G, Maitra A, Zamboni G (2019) Pancreatic intraductal oncocytic papillary neoplasm. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system, 5th edn. IARC, Lyon, pp 315–316
3. Jyotheeswaran S, Zotalis G, Penmetsa P et al (1998) A newly recognized entity: intraductal “oncocytic” papillary neoplasm of the pancreas. Am J Gastroenterol 93:2539–2543. https://doi.org/10.1111/J.1572-0241.1998.00714.X
4. Reid MD, Stallworth CR, Lewis MM et al (2016) Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: criteria and clinical implications of accurate diagnosis. Cancer Cytopathol 124:122–134. https://doi.org/10.1002/CNCY.21627
5. Mattiolo P, Hong SM, Paolino G et al (2020) CD117 is a specific marker of intraductal papillary mucinous neoplasms (IPMN) of the pancreas, Oncocytic Subtype. Int J Mol Sci 21:5794. https://doi.org/10.3390/IJMS21165794
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献